Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner
Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Figure 6: The CML Therapy Matrix with Complete CR Estimates

Previous Therapy Phase
Chronic phase Accelerated phase Blastic phase/blast crisis
Extent of Previous Therapy Newly diagnosed Phase III:
I: 74%59
IFN + AraC:
9%,59 15%42
IFN alone: 9%42

Phase II:
I 60-81%63,98
Historical control (includes IFN):
5-32%63,98

I: 11-19%82,87
Estimated IFN: <5%
I: 0-10%3,4,89,90
Estimated IFN: <<5%
Interferon refractory or intolerant I: 31-62%2,44,73,148
Historical control with IFN: 7-19%44
I: 11-19%82,87
Estimated IFN: <5%
I: 0-10%3,4,89,90
Estimated IFN: <<5%
Previous stem cell transplant/heavily pretreated I: 33-85%37,77-81 Historical control with IFN: 7-19%44 (from above) I: 11-19%82,87
Estimated IFN: <5%
I: 0-10%3,4,89,90
Estimated IFN: <<5%
Imatinib refractory or intolerant Future Directions Future Directions Future Directions

Return to Document
Proceed to Figure 7

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care